Lawsuit for Investors in Shares of TESARO Inc. (NASDAQ: TSRO) Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / January 30, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in TESARO Inc. (NASDAQ: TSRO) shares.

Investors who purchased shares of TESARO Inc. (NASDAQ: TSRO) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On January 12, 2018, TESARO Inc. announced that it had updated the U.S. labeling for Varubi (rolapitant), indicated for the prevention of delayed nausea and vomiting associated with chemotherapy, after receiving reports of “[a]naphylaxis, anaphylactic shock and other serious hypersensitivity reactions . . . in the postmarketing setting, some requiring hospitalization.” TESARO Inc. further stated that it “has issued a Dear Healthcare Professional (DHCP) letter.”

On January 17, 2017, a securities class action lawsuit was filed TESARO Inc. over alleged violations of Federal Securities Laws. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that substantial undisclosed health risks, including anaphylaxis and anaphylactic shock, were associated with Tesaro’s intravenous formulation of Varubi, and that as a result of the foregoing, Tesaro’s shares traded at artificially inflated prices between March 14, 2016 and January 12, 2018, and class members suffered significant losses and damages.

Those who purchased TESARO Inc. (NASDAQ: TSRO) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 487311